JAK3 binds JAK3 inhibitors

Stable Identifier
R-HSA-9679028
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Janus Kinase 3 (JAK3) binds and is inhibited by several small molecule drugs (Clark et al. 2014, Changelian et al. 2003, Flanagan et al. 2010, Dhillon 2017, Chi et al. 2020). The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases such as baricitinib, tofacitinib, ruxolitinib and tofacitinib are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Peterson et al. 2020, Richardson et al. 2020).

Literature References
PubMed ID Title Journal Year
24417533 Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

Clark, JD, Flanagan, ME, Telliez, JB

J. Med. Chem. 2014
29139090 Tofacitinib: A Review in Rheumatoid Arthritis

Dhillon, S

Drugs 2017
31918398 JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma

Chi, F, Chen, L, Wang, C, Li, L, Sun, X, Xu, Y, Ma, T, Liu, K, Ma, X, Shu, X

Bioorg. Chem. 2020
14593182 Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor

Changelian, PS, Flanagan, ME, Ball, DJ, Kent, CR, Magnuson, KS, Martin, WH, Rizzuti, BJ, Sawyer, PS, Perry, BD, Brissette, WH, McCurdy, SP, Kudlacz, EM, Conklyn, MJ, Elliott, EA, Koslov, ER, Fisher, MB, Strelevitz, TJ, Yoon, K, Whipple, DA, Sun, J, Munchhof, MJ, Doty, JL, Casavant, JM, Blumenkopf, TA, Hines, M, Brown, MF, Lillie, BM, Subramanyam, C, Shang-Poa, C, Milici, AJ, Beckius, GE, Moyer, JD, Su, C, Woodworth, TG, Gaweco, AS, Beals, CR, Littman, BH, Fisher, DA, Smith, JF, Zagouras, P, Magna, HA, Saltarelli, MJ, Johnson, KS, Nelms, LF, Des Etages, SG, Hayes, LS, Kawabata, TT, Finco-Kent, D, Baker, DL, Larson, M, Si, MS, Paniagua, R, Higgins, J, Holm, B, Reitz, B, Zhou, YJ, Morris, RE, O'Shea, JJ, Borie, DC

Science 2003
21105711 Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

Flanagan, ME, Blumenkopf, TA, Brissette, WH, Brown, MF, Casavant, JM, Shang-Poa, C, Doty, JL, Elliott, EA, Fisher, MB, Hines, M, Kent, C, Kudlacz, EM, Lillie, BM, Magnuson, KS, McCurdy, SP, Munchhof, MJ, Perry, BD, Sawyer, PS, Strelevitz, TJ, Subramanyam, C, Sun, J, Whipple, DA, Changelian, PS

J. Med. Chem. 2010
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!